[3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-[(R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)propyl]amine | 885220-62-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: [3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-[(R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)propyl]amine
• 英文别名: 3-(4-methoxy-2-methylphenyl)-2,5-dimethyl-N-[(1R)-1-(3-methyl-1,2,4-oxadiazol-5-yl)propyl]pyrazolo[1,5-a]pyrimidin-7-amine
• CAS: 885220-62-2
• 化学式: C₂₂H₂₆N₆O₂
• 分子量: 406.487
• InChiKey: VKHVAUKFLBBZFJ-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  30
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  90.4
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  在 吡啶 作用下， 生成 [3-(4-methoxy-2-methylphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-yl]-[(R)-1-(3-methyl-[1,2,4]oxadiazol-5-yl)propyl]amine
  参考文献：
  名称：

  Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties

  摘要：

  Antagonists of the corticotropin-releasing factor (CRF) neuropeptide may prove effective in treating stress and anxiety related disorders. In an effort to identify antagonists with improved physico-chemical properties a new series of CRF1 antagonists were designed to substitute the propyl groups at the C7 position of the pyrazolo[1,5-a]pyrimidine core of 1 with heterocycles. Compound (S)-8d was identified as a high affinity ligand with a pK(i) value of 8.2 and a functional CRF1 antagonist with pIC(50) value of 7.0 in the in vitro CRF ACTH production assay. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.095

文献信息

• Pyrazolo[1,5-Alpha]Pyrimidinyl Derivatives Useful as Corticotropin-Releasing Factor (Crf) Receptor Antagonists
  申请人：Lanier Marion

  公开号：US20080194589A1

  公开（公告）日：2008-08-14

  CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R 1 , R 2a , R 2b , Y, Het, n, o, R 6 , Ar and R 7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

  本发明揭示了CRF受体拮抗剂，可能在治疗多种疾病方面有用，包括治疗哺乳动物CRF过度分泌引起的疾病。本发明的CRF受体拮抗剂具有以下结构：（I）；以及其药物学上可接受的盐，酯，溶剂合物，立体异构体和前药，其中R1，R2a，R2b，Y，Het，n，o，R6，Ar和R7如本文所定义。还揭示了含有CRF受体拮抗剂与药学可接受载体组合的组合物，以及使用它们的方法。
• PYRAZOLO (1,5-ALPHA) PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS
  申请人：SB Pharmco Puerto Rico Inc.

  公开号：EP1802627A1

  公开（公告）日：2007-07-04
• US7879862B2
  申请人：——

  公开号：US7879862B2

  公开（公告）日：2011-02-01
• [EN] PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS<br/>[FR] DERIVES DE PYRAZOLO[1,5-ALPHA]PYRIMIDINYLE UTILES COMME ANTAGONISTES VIS-A-VIS DU RECEPTEUR DU FACTEUR DE LIBERATION DE LA CORTICOTROPINE (CRF)
  申请人：SB PHARMCO INC

  公开号：WO2006044958A1

  公开（公告）日：2006-04-27

  [EN] CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R[FR] L'invention concerne des antagonistes vis-à-vis du récepteur CRF pouvant être utiles dans le traitement de divers troubles, y compris le traitement des troubles qui se manifestent par une hypersécrétion du CRF chez les mammifères. Les antagonistes ont la structure ci-après (I). Les antagonistes s'entendent aussi des sels, esters, solvates, stéréoisomères et promédicaments pharmaceutiquement acceptables, et pour les besoins de la formule décrite, R
• [EN] COMPOUNDS FOR TREATMENT OF EMOTIONAL/PSYCHOLOGICAL SYMPTOMS IN FRAGILE X SYNDROME<br/>[FR] COMPOSÉS POUR LE TRAITEMENT DE SYMPTÔMES ÉMOTIONNELS/PSYCHOLOGIQUES DANS LE SYNDROME DE L'X FRAGILE
  申请人：VANDERKLISH PETER

  公开号：WO2019075394A1

  公开（公告）日：2019-04-18

  The invention is directed, in various embodiments, to methods of treatment of the emotional or psychological symptoms of Fragile X Syndrome (FXS) in human patients by administration of an effective dose of a compound that is an inhibitor of the cortisol synthetic enzyme 11β-hydroxysteroid dehydrogenase type 1 (HSD11β1) or an effective dose of an antagonist of the corticotropin releasing hormone (CRH) receptor. For instance, an effective dose of one of these two classes of drugs is administered to a patient for treatment when the emotional and psychological symptom of FXS comprises chronic anxiety in any form, social aversion, obsessive compulsive behaviors, aggression, agitation, self injurious behavior, or any combination thereof.